*Average value ± SD, **Median-mean value, and n.d.: not done. During organ injury, endogenous HGF is delivered through endocrine and paracrine pathways and contributes to an increase in blood HGF levels [10]. HGF seems to be present in blood in an inactive form (i.e., pro-HGF) [62]. Thus, a rapid administration of recombinant HGF (i.e., active HGF) may be recommended under pathological conditions. Pharmacological levels of recombinant HGF in blood can be sustained within a range of 3–30 ng/mL, by modifying the injection doses and their intervals [15, 32].